Mineralys Therapeutics, Inc. financial data

Symbol
MLYS on Nasdaq
Industry
Pharmaceutical Preparations
Location
150 N. Radnor Chester Road, Suite F200, Radnor, Pennsylvania
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.29K %
Return On Equity -32.5 % +61.9%
Return On Assets -31.1 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.6M shares +21.5%
Common Stock, Shares, Outstanding 49.6M shares +21.5%
Entity Public Float 240M USD
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 44.9M shares +81.3%
Weighted Average Number of Shares Outstanding, Diluted 44.9M shares +81.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 88.8M USD +180%
General and Administrative Expense 16.3M USD +130%
Operating Income (Loss) -105M USD -170%
Nonoperating Income (Expense) 14.3M USD +256%
Net Income (Loss) Attributable to Parent -90.8M USD -161%
Earnings Per Share, Basic -2.18 USD/shares +54.6%
Earnings Per Share, Diluted -2.18 USD/shares +54.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 90.4M USD -34.6%
Assets, Current 347M USD +26%
Property, Plant and Equipment, Net 51K USD
Other Assets, Noncurrent 379K USD +872%
Assets 347M USD +13.3%
Accounts Payable, Current 4.26M USD +78.5%
Accrued Liabilities, Current 14.9M USD +82.8%
Liabilities, Current 19.2M USD +81.9%
Retained Earnings (Accumulated Deficit) -156M USD -139%
Stockholders' Equity Attributable to Parent 328M USD +10.9%
Liabilities and Equity 347M USD +13.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -19.1M USD -49.8%
Net Cash Provided by (Used in) Financing Activities 116M USD -42.9%
Net Cash Provided by (Used in) Investing Activities -56M USD +60.1%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 49.6M shares +21.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 41.1M USD -18.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 90.4M USD -34.6%
Deferred Tax Assets, Valuation Allowance 31.5M USD +144%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 31.5M USD +144%
Deferred Income Tax Expense (Benefit) 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 7.89M USD +37.5%
Current Income Tax Expense (Benefit) 0 USD
Unrecognized Tax Benefits 1.08M USD +312%
Additional Paid in Capital 484M USD +34%
Depreciation, Depletion and Amortization 8K USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 6.5M USD +449%